BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34004092)

  • 1. Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study.
    Chen YQ; Li XR; Zhang L; Zhu WB; Wu YQ; Guan XN; Xiu MH; Zhang XY
    J Clin Psychiatry; 2021 May; 82(3):. PubMed ID: 34004092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study.
    Shi H; Guan XN; Liu DY; Zhu L; Wu ZW; Luo GZ; Wang J; Xiu MH; Zhang XY
    Pharmacopsychiatry; 2021 Mar; 54(2):68-74. PubMed ID: 33626593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.
    Luckhoff H; Phahladira L; Scheffler F; Asmal L; du Plessis S; Chiliza B; Kilian S; Emsley R
    Schizophr Res; 2019 Apr; 206():171-176. PubMed ID: 30503765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study.
    Gao Z; Xiu M; Liu J; Wu F; Zhang X
    Curr Neuropharmacol; 2024; 22(10):1733-1741. PubMed ID: 37859307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.
    Nielsen MØ; Rostrup E; Wulff S; Glenthøj B; Ebdrup BH
    JAMA Psychiatry; 2016 Feb; 73(2):121-8. PubMed ID: 26747088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
    Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
    Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
    [No Abstract]   [Full Text] [Related]  

  • 9. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study.
    Liu J; Wang P; Sun L; Guan X; Xiu M; Zhang X
    Transl Psychiatry; 2021 Sep; 11(1):458. PubMed ID: 34482368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
    Strassnig M; Miewald J; Keshavan M; Ganguli R
    Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
    Schimmelmann BG; Mehler-Wex C; Lambert M; Schulze-zur-Wiesch C; Koch E; Flechtner HH; Gierow B; Maier J; Meyer E; Schulte-Markwort M
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):768-78. PubMed ID: 18315449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
    Weiser M; Levi L; Zamora D; Biegon A; SanGiovanni JP; Davidson M; Burshtein S; Gonen I; Radu P; Slobozean Pavalache K; Nastas I; Hemi R; Ryan T; Davis JM
    JAMA Psychiatry; 2019 Oct; 76(10):1009-1017. PubMed ID: 31365044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.
    Li XR; Xiu MH; Guan XN; Wang YC; Wang J; Leung E; Zhang XY
    Neurotherapeutics; 2021 Apr; 18(2):1316-1324. PubMed ID: 33791970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
    Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
    Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
    Lane HY; Chang YC; Cheng YC; Liu GC; Lin XR; Chang WH
    J Clin Psychiatry; 2003 Mar; 64(3):316-20. PubMed ID: 12716274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.